|
Dotmatics Introduces Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery
Friday, October 25, 2024
The first in a series of Dotmatics Luma Multimodal R&D Solutions
Geneious has been seamlessly composed into Luma showcasing cross-therapeutic capabilities within a unified platform
BOSTON, Oct. 22, 2024 /PRNewswire/ -- Dotmatics(®), a leader in R&D scientific software connecting science, data, and decision-making, today announced the launch of Dotmatics Luma(TM) Multimodal R&D Solutions in support of the discovery and development of therapeutics across multiple modalities of biopharmaceutical science. The first solution is the Luma Antibody & Protein Engineering solution, a comprehensive end-to-end solution for streamlining the antibody discovery and development process, with an emphasis on monoclonal and multispecific antibodies.
The Luma Antibody & Protein Engineering Solution and other future multimodal solutions combine the Dotmatics Luma Scientific Intelligence Platform and key Dotmatics scientific tools, thoughtfully composed within Luma. Together, these solutions will offer researchers a multimodal approach to therapeutic discovery supporting CAR-T cell discovery, siRNA, antibody-drug conjugates (ADCs), CRISPR therapeutics, and vaccine discovery.
"Increasingly our customers are asking for tools that support multiple modalities of therapeutic discovery," said Michael Swartz, Chief Strategy Officer at Dotmatics. "Scientists want to pick the best therapy or combination of therapies to address a particular target by researching and testing across different domains of science - not just one. Dotmatics gives them a scientific intelligence platform that is natively built to support this."
These multimodal Luma solutions will leverage capabilities from Dotmatics' best-in-class scientific software products including Geneious(®), GraphPad(®) Prism, OMIQ(®), Protein Metrics Byos(®), and FCS Express(®), composed to work together harmoniously within Luma, enhancing overall functionality without friction. This approach allows researchers to use familiar tools while eliminating data and process silos, creating a more cohesive and collaborative environment.
Introducing Geneious Luma
The first of these scientific products seamlessly composed within Luma and being introduced today is Geneious Luma. With Geneious Luma, researchers will have access to analyze and visualize DNA, RNA, and protein sequences from Geneious Prime, and the antibody discovery and screening capabilities of Geneious Biologics.
Geneious Luma, and the other future Dotmatics scientific products composed within Luma, will each come pre-configured to work seamlessly within Luma, while allowing IT and scientists to compose their own sequence of sophisticated low-code actions, eliminating the need for lengthy customization or complex integrations. As a result, researchers can benefit from the end-to-end solution immediately. In addition, these products will be available to license together with the Luma platform and will include out-of-the-box Luma applications to fill critical gaps in the end-to-end workflow, including:
-- Multimodal Registration: Versioned, entity-specific, and extensible
registration models driven by linked ontologies allow for the highest
levels of scientific depth and precision. Luma links these models to how
scientists naturally work, so registration happens automatically and
asynchronously, along with the tracking and storage of experimental and
product-related information throughout the research and development
process. When test results indicate a synthesized molecule does not
match the design, Luma can modify the linked registered entity without
losing lineage or context of the original.
-- Unified Results: All relevant project data--such as molecule designs,
characterization data, assay data, endpoint data, and registered
materials--can be correlated and unified into normalized data structures
and customizable dashboards to quickly make decisions about which
antibodies are best to advance. This happens automatically as people
work, eliminating the need for hours of data wrangling currently
implicit in activities from registration to analysis.
-- Customer Apps: Customers can safely extend Dotmatics Luma apps or create
their own low-code apps to contextualize, flow, and correlate data from
disparate sources in ways that suit their needs - with scientifically
smart dashboards and visualizations to match. These apps follow industry
standard SDLC processes and FAIR data principles to make getting data
into and out of Luma in a governed way simple and straightforward. Data
integration options include REST, GraphQL, and JDBC.
-- Artificial Intelligence: Luma will include significant generative and
predictive ML capabilities for dry lab and wet lab tasks that customers
can define and extend. Assistive GenAI will help customers accelerate
the introspection, summarization, and visualization of their data.
Domain-specific AI will allow Luma to leverage protein prediction, flow
cytometry autogating, and other scientifically-focused models within
their workflows. Composite AI will allow the use of multiple models or
data sets generated from independent models to be brought together for
higher order model training, selection, and execution.
The Luma Antibody & Protein Engineering Solution
By composing Geneious Luma and other scientific products within Luma, Dotmatics can offer researchers with a new solution for addressing the complexities of antibody and protein engineering.
"The Luma Antibody & Protein Engineering solution addresses long-standing gaps in the antibody discovery workflow by providing an end-to-end process that seamlessly composes many of scientists' favorite tools directly into Luma," said Kalim Sailba, Chief Product Officer at Dotmatics. "Researchers can now streamline workflows from planning and in-silico design to wet lab production, validation, and data analysis, all within a unified AI-native platform."
The following products, composed within Luma, will support the Luma Antibody & Protein Engineering solution:
-- Geneious Luma: Enables researchers to use the advanced bioinformatics,
molecular biology, and antibody discovery capabilities of Geneious
Prime(®) and Geneious Biologics(®) to annotate and filter sequences
and to design constructs. Then, seamlessly working together with Luma,
researchers can execute their cloning, expression, and purification
tasks using Luma's Adaptive Workflow capabilities.Customers will also
have access to BioGlyph(®), following Dotmatics' recent investment,
enabling the design and generation of multispecific antibody formats and
the execution of predictive machine learning models to score potential
multispecific antibodies, allowing researchers to explore all
combinations of multispecific formats and proceed with only those that
are most promising.
-- Prism Luma: Leverage GraphPad Prism, the industry-leading data analysis
software, for antibody assay development and screening. This product
includes native normalization and pre-processing of results prior to
analysis in Prism (mitigating the need to use Excel) and contextual
linking between assay results, registered materials, and experimental
context.
-- Byos & Byosphere Luma: Use Protein Metrics Byos, a comprehensive
software for streamlining protein characterization, to characterize
protein structures and behaviors for higher fidelity, then feed these
characterizations back into predictive machine learning models to drive
the next round of synthesis. Also leverage Protein Metrics Byosphere
enterprise platform to combine biotherapeutic mass spec data, analysis,
and reporting and to curate, interrogate, and share information gained
in the analytical lab from Byos.
-- Luma Lab Connect: Automate data ingestion from lab instruments
including flow cytometry, liquid chromatography, mass spectrometry and
other data sources. Lab Connect auto-associates instrument results with
the correct workflow steps, materials, and endpoint data, mitigating a
common manual pain point of SDMS and LIMS systems today.
-- Flow Luma: Use OMIQ, the modern flow cytometry solution, to evaluate the
molecular properties of antibody candidates, the cells that produce
them, and phenotype their therapeutic outcomes.
Expanding Beyond Biopharma
The future use of Dotmatics Luma extends beyond biopharma and drug discovery into broader scientific domains, like material science and chemistry, industrial biotech, and agritech. Every solution built on the Luma platform ensures a unified user experience and seamless work and data flows, helping organizations achieve scientific breakthroughs faster and with greater accuracy. By delivering a cohesive and scalable platform, Dotmatics aims to support researchers across multiple industries, fostering innovation and collaboration.
Forward Looking Statements
This press release contains forward-looking statements that are intended to outline our general product strategy. It is intended for informational purposes only and speaks only as of the date the statements are first published. It is not a commitment to deliver any functionality and should not be relied upon for making purchase decisions. You should not put any contractual reliance on these statements. The development, release, and timing of any products or capabilities remains at the sole discretion of Dotmatics.
No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. Only those representations or warranties that are made in or pursuant to one or more definitive agreements involving the parties will have any legal effect.
About Dotmatics
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists' favorite applications drive efficiency and accelerate innovation. More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. Dotmatics has made 14 acquisitions since 2017. The company's principal office is in Boston, with 14 offices and R&D teams located around the world.
Dotmatics is backed by Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software scaleup companies. Learn more about Dotmatics, its platform, and applications including GraphPad Prism, Geneious, SnapGene, Protein Metrics, and LabArchives at https://www.dotmatics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/dotmatics-introduces-luma-antibody--protein-engineering-solution-for-end-to-end-antibody-discovery-302282480.html
SOURCE Dotmatics Inc
|
|
|
|
|
|
 |
Climate and Energy Analytics Startup Sunairio Raises $6.4 Million to Help Energy Sector Navigate Unprecedented Grid Volatility | Dec 28, 2024
|
|
Expand the Boundaries of Technology and Service, Baijiayun's "DuanXunBao" Ushered in a Winter Refresh and Upgrade | Dec 28, 2024
|
|
HealthQuest Capital Invests in Royal Health Inc to Accelerate Innovation in Radiology Operational Solutions | Dec 28, 2024
|
|
Tenant, Inc. and Storelocal Storage Team Up with OC Rescue Mission for Holiday Donation Drive | Dec 28, 2024
|
|
Global Times: Xi stresses adherence to 'one country, two systems' as Macao celebrates 25th anniversary of return to motherland | Dec 28, 2024
|
|
Schneider Electric India Recognized by Frost & Sullivan as the Indian Company of the Year 2024 | Dec 28, 2024
|
|
Founder Shares Unforgettable Lessons After Spending $1 Million on a Domain Name | Dec 28, 2024
|
|
Quantiphi Joins AWS Generative AI Partner Innovation Alliance | Dec 27, 2024
|
|
Luminys and Foxlink Collaboration: Advancing AI-Driven Innovations in Security Solutions | Dec 27, 2024
|
|
Hyperlink InfoSystem An Official Salesforce Consulting Partner | Dec 27, 2024
|
|
|
|
